Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Aptorum Group Ltd Cl A (APM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Aptorum Group Announces Merger with DiamiR Biosciences Tipranks - Thu Oct 16, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

Aptorum Group Announces Strategic Merger with DiamiR Biosciences Tipranks - Thu Oct 9, 2025

Aptorum Group Releases Interim Financial Results for June 2025 Tipranks - Sat Oct 4, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptorum Group...

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency Business Wire - Fri May 5, 2023

Regulatory News:

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited Business Wire - Mon May 1, 2023

Regulatory News:

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update Business Wire - Fri Apr 28, 2023

Regulatory News:

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group Business Wire - Mon Mar 27, 2023

Regulatory News:

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus Business Wire - Fri Mar 3, 2023

Regulatory News:

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma Business Wire - Fri Mar 3, 2023

Regulatory News: